Akr1c13 Antibody

What is AKR1C3 and why is it significant in research?

AKR1C3 (Aldo-keto reductase family 1 member C3) is an enzyme also known as DDH1, HSD17B5, KIAA0119, and PGFS, belonging to the AKR1C family. In humans, at least four AKR1C isoforms exist (AKR1C1, AKR1C2, AKR1C3, and AKR1C4), with AKR1C3 sharing >86% sequence identity with the other members . This protein is particularly significant in research due to its roles in steroid hormone metabolism, prostaglandin synthesis, and involvement in various cancer types, including prostate cancer. AKR1C3's ability to regulate androgen synthesis and metabolism makes it a critical target in hormone-dependent cancer research and potential therapeutic development .

What are the key differences between AKR1C3 and other AKR1C family members?

While AKR1C family members share high sequence homology (>86%), AKR1C3 has distinct substrate preferences and tissue expression patterns compared to AKR1C1, AKR1C2, and AKR1C4 . The primary distinctions include:

• Substrate specificity: AKR1C3 functions as a 17β-hydroxysteroid dehydrogenase and has higher affinity for certain androgen precursors

• Tissue distribution: AKR1C3 shows differential expression across tissues compared to other family members

• Cancer relevance: AKR1C3 is particularly implicated in hormone-dependent cancers, especially prostate cancer

• Molecular weight: AKR1C3 has a calculated molecular weight of 37 kDa but is typically observed at 34 kDa in western blotting applications

These differences highlight the importance of using specific antibodies that can distinguish AKR1C3 from other family members in research applications.

How should I optimize AKR1C3 antibody selection for specific experimental needs?

Selecting the appropriate AKR1C3 antibody requires consideration of several factors:

• Antibody specificity: Compare different antibodies for cross-reactivity with other AKR1C family members. Research indicates that monoclonal antibodies like Sigma/Millipore's mouse monoclonal (clone NP6.G6.A6) show higher specificity compared to some polyclonal options .

• Application compatibility: Verify the antibody's validated applications. For example, antibody 11194-1-AP is validated for WB, IHC, IP, and ELISA applications with human samples .

• Control selection: Include appropriate positive and negative controls. For example, HCT116 cells have been used as a negative control, while genetically modified HCT116 cells with AKR1C3 overexpression serve as positive controls .

• Clone comparison: When multiple options are available, test different clones:

  • Polyclonal Thermofisher scientific (Clone#PA523667)

  • Rabbit monoclonal Abcam [EPR16726] (ab209899)

  • Sigma/Millipore mouse monoclonal (clone NP6.G6.A6)

Comparative testing with these antibodies has shown that the Sigma/Millipore clone demonstrates superior specificity for AKR1C3 detection, particularly for immunohistochemistry applications .

What are the optimal protocols for AKR1C3 detection in immunohistochemistry?

For optimal AKR1C3 detection in immunohistochemistry:

• Antigen retrieval: Use TE buffer pH 9.0 as the primary method. Alternatively, citrate buffer pH 6.0 may be used if needed .

• Antibody dilution: Start with a dilution range of 1:50-1:500 and optimize based on your specific tissue samples .

• Quantification method: For semi-quantitative analysis, the H-score can be used to quantify the percentage of nuclear immunoreactivity, which has proven effective in studies of T-ALL and B-ALL samples .

• Antibody selection: Sigma/Millipore Anti-AKR1C3 antibody (mouse monoclonal, clone NP6.G6.A6) has demonstrated higher specificity compared to rabbit polyclonal antibodies in comparative studies .

• Controls: Include appropriate positive controls (such as prostate cancer tissue) and negative controls (tissues known to lack AKR1C3 expression) .

When examining leukemia samples, researchers have observed that T-ALL samples typically show higher H-scores (172-190) compared to B-ALL cases (H-scores of 30-160) , which can serve as a reference point for expected staining intensity.

What considerations are important for western blotting with AKR1C3 antibodies?

For successful western blotting of AKR1C3:

• Expected molecular weight: AKR1C3 has a calculated molecular weight of 37 kDa, but is typically observed at 34 kDa on western blots . This discrepancy should be considered when interpreting results.

• Recommended dilution: Use a dilution range of 1:500-1:2000, with optimization for specific sample types .

• Positive controls: A549 cells, HepG2 cells, Jurkat cells, and K-562 cells have been verified as positive controls for AKR1C3 western blotting .

• Sample preparation: Standard RIPA buffer extraction is typically sufficient, but optimization may be required for specific tissue types.

• Membrane blocking: 5% non-fat dry milk in TBST is recommended for blocking, although 5% BSA may be used if background is problematic.

• Confirmation method: Consider validation with a second antibody or using siRNA knockdown to confirm specificity, especially when evaluating AKR1C3 in new cell types or tissues.

How can AKR1C3 antibodies be utilized to detect minimal residual disease in leukemia?

AKR1C3 expression has emerged as a potential method for detecting minimal residual disease (MRD) in T and B-ALL patients . The methodology involves:

• Antibody selection: Sigma/Millipore Anti-AKR1C3 antibody (mouse monoclonal, clone NP6.G6.A6) has demonstrated superior specificity for this application .

• Multi-method approach: Combine immunohistochemistry with molecular techniques for comprehensive assessment:

  • Immunohistochemistry with H-score quantification for tissue samples

  • Protein Wes analysis for protein expression in peripheral blood

  • Quantitative RT-PCR for gene expression analysis

• Differential expression analysis: Utilize the finding that T-ALL samples typically display higher H-scores (172-190) compared to B-ALL cases (H-scores of 30-160) .

• Validation: Studies have shown concordance between AKR1C3 expression detected by Protein Wes and RT-qPCR methods in relapsed/refractory and minimal residual T-ALL cases, supporting the reliability of this approach .

This multi-modal approach allows researchers to track treatment response and detect early relapse in leukemia patients, potentially improving clinical outcomes through earlier intervention.

What role do AKR1C3 antibodies play in studying PROTAC-based degraders?

AKR1C3 antibodies are instrumental in studying Proteolysis Targeting Chimera (PROTAC) technologies directed at AKR1C3 degradation:

• Mechanism validation: Antibodies help confirm that PROTACs successfully engage and degrade AKR1C3 protein in experimental models .

• Quantification of degradation: Western blotting with AKR1C3 antibodies allows researchers to measure the extent and kinetics of protein degradation after PROTAC treatment .

• Cell line selection: Antibody-based screening helps identify appropriate cell models with varying AKR1C3 expression levels:

  • 22Rv1 cells (moderate expression)

  • 22Rv1 cells grown in charcoal-stripped serum (high expression)

  • LNCaP cells (AKR1C3 null)

  • AKR1C3 stably transfected LNCaP1C3 cells

• Target specificity: AKR1C3 antibodies help confirm that degraders specifically target AKR1C3 without affecting other AKR1C family members by enabling western blot analysis of all family members simultaneously.

In recent research, AKR1C3 antibodies have facilitated the development of PROTAC 5, which combines an AKR1C3 inhibitor warhead with the cereblon ligand lenalidomide, demonstrating selective degradation of AKR1C3 with potential therapeutic applications in prostate cancer .

How can AKR1C3 antibodies be employed in multiplexed detection systems?

Multiplexed detection of AKR1C3 alongside other biomarkers can provide comprehensive insights into disease mechanisms. Implementation strategies include:

• Multiplex immunofluorescence: Combine AKR1C3 antibody with antibodies against other relevant proteins:

  • Use species-distinct primary antibodies (e.g., rabbit anti-AKR1C3 with mouse anti-androgen receptor)

  • Employ fluorophore-conjugated secondary antibodies with non-overlapping emission spectra

  • Include nuclear counterstains (e.g., DAPI) for cellular context

• Sequential immunohistochemistry: For tissues where multiplex immunofluorescence is challenging:

  • Utilize sequential staining protocols with stripping or quenching steps between biomarkers

  • Document slide locations to facilitate co-registration of images

• Complementary protein detection: Combine with antibodies against functionally related proteins:

  • Other AKR1C family members to assess isoform specificity

  • Steroid hormone receptors to correlate with AKR1C3 activity

  • Proliferation markers to associate with cellular function

• Validation strategies: For each multiplexed application:

  • Perform single-plex controls to confirm antibody performance is maintained

  • Include appropriate isotype controls to assess background

  • Verify staining patterns match those observed in single-marker experiments

These approaches allow researchers to simultaneously evaluate AKR1C3 expression in relation to other relevant biomarkers, enhancing understanding of its biological context.

How should discrepancies in AKR1C3 antibody results be investigated and resolved?

When encountering inconsistent results with AKR1C3 antibodies:

• Antibody specificity assessment:

  • Compare results using multiple antibody clones (e.g., Sigma/Millipore mouse monoclonal vs. Abcam rabbit monoclonal)

  • Perform knockdown/knockout validation experiments

  • Include recombinant AKR1C3 protein as a positive control

• Cross-reactivity investigation:

  • Test antibody against other AKR1C family members (AKR1C1, AKR1C2, AKR1C4)

  • Perform peptide competition assays to confirm epitope specificity

  • Consider testing in AKR1C3-null cell lines like LNCaP

• Technical optimization:

  • Adjust antibody concentrations across a wide range

  • Modify antigen retrieval methods (compare TE buffer pH 9.0 vs. citrate buffer pH 6.0)

  • Evaluate different detection systems (HRP-based vs. fluorescent)

• Sample-specific considerations:

  • Verify protein extraction efficiency

  • Assess potential post-translational modifications affecting epitope recognition

  • Consider sample-specific matrix effects

When experiencing discrepancies, validating results with orthogonal techniques (e.g., mass spectrometry, gene expression analysis) can provide additional confirmation of AKR1C3 identity and expression levels.

What standards should be applied when quantifying AKR1C3 expression in immunohistochemistry?

For reliable quantification of AKR1C3 expression in immunohistochemistry:

• Standardized scoring system:

  • Implement the H-score method to quantify nuclear immunoreactivity percentage

  • Calculate H-score as: ∑(percentage of cells with intensity category × intensity category value)

  • Use established reference ranges: T-ALL (172-190) vs. B-ALL (30-160)

• Technical standardization:

  • Maintain consistent staining conditions across batches

  • Include reference standard slides in each batch

  • Utilize automated staining platforms when possible

• Observer consistency:

  • Employ multiple independent observers for scoring

  • Calculate inter-observer agreement statistics

  • Consider digital pathology approaches for objective quantification

• Validation approaches:

  • Correlate IHC findings with western blot or Protein Wes results

  • Compare with quantitative RT-PCR data for concordance

  • Assess biological relevance through correlation with clinical outcomes

Following these standardized approaches enhances reproducibility and comparability of AKR1C3 expression data across different studies and laboratories.

How can researchers differentiate between AKR1C3 and other AKR1C family members in experimental systems?

Distinguishing AKR1C3 from its closely related family members requires:

• Antibody selection strategy:

  • Prioritize monoclonal antibodies developed against unique epitopes

  • Sigma/Millipore mouse monoclonal (clone NP6.G6.A6) has demonstrated higher specificity compared to polyclonal alternatives

  • Verify epitope sequences against all AKR1C family members for predicted specificity

• Experimental validation:

  • Test antibodies on recombinant proteins for all four AKR1C isoforms

  • Employ knockout/knockdown models for specificity confirmation

  • Use cell lines with known differential expression of AKR1C family members

• Molecular approaches:

  • Complement protein detection with isoform-specific PCR primers

  • Consider RNA interference techniques targeting unique regions

  • Use gene editing (CRISPR/Cas9) to create specific knockout models

• Functional validation:

  • Assess enzymatic activity with isoform-specific substrates

  • Evaluate inhibitor sensitivity profiles that differ between isoforms

  • Correlate expression with known functional outcomes

These comprehensive approaches ensure accurate discrimination between AKR1C3 and its family members, which is crucial for accurate experimental interpretation given their high sequence homology.

What emerging roles for AKR1C3 antibodies exist in targeted cancer therapy research?

AKR1C3 antibodies are increasingly valuable in targeted cancer therapy research:

• PROTAC development:

  • Antibodies verify target engagement and degradation in novel AKR1C3-targeting PROTACs

  • Recent research has developed hybrid AKR1C3 inhibitor warheads linked to cereblon ligands like lenalidomide

  • These studies employed AKR1C3 antibodies to confirm protein degradation in prostate cancer cell models

• Patient stratification biomarker:

  • AKR1C3 antibodies help identify patients likely to respond to specific therapies

  • Expression levels detected by IHC correlate with susceptibility to AKR1C3-targeted compounds

  • Differential expression patterns in T-ALL vs. B-ALL may guide treatment selection

• Combination therapy assessment:

  • Antibody-based detection monitors AKR1C3 modulation during combination treatments

  • Post-treatment changes in expression guide sequential therapy approaches

  • Resistant phenotypes can be characterized by antibody-based techniques

• Minimal residual disease detection:

  • AKR1C3 antibodies show promise for detecting residual disease in leukemia patients

  • The approach combines IHC, Protein Wes, and qRT-PCR for comprehensive assessment

These applications highlight how AKR1C3 antibodies are evolving from basic research tools to critical components of translational cancer research with direct clinical implications.

How do different cell and tissue types influence AKR1C3 antibody performance?

AKR1C3 antibody performance varies across cell and tissue types due to several factors:

• Expression level variations:

  • Prostate cancer tissues typically show high AKR1C3 expression, facilitating detection

  • T-ALL samples demonstrate higher H-scores (172-190) than B-ALL cases (30-160)

  • Cell lines show variable expression: moderate in 22Rv1, high in 22Rv1 with charcoal-stripped serum, null in LNCaP

• Tissue-specific protocols:

  • Prostate cancer tissue: Recommended antigen retrieval with TE buffer pH 9.0; alternatively, citrate buffer pH 6.0

  • Blood and bone marrow: Special preparation techniques required for optimal antibody performance

  • Cell lines: Standard fixation protocols generally yield satisfactory results

• Background considerations:

  • Tissues with high lipid content may require additional blocking steps

  • Endogenous peroxidase activity varies by tissue and requires appropriate quenching

  • Auto-fluorescence can impact immunofluorescence applications in certain tissues

• Validation approaches by tissue type:

  • For leukemia: Compare with Protein Wes and RT-qPCR results

  • For solid tumors: Correlate with known expression patterns and functional outcomes

  • For cell lines: Validate with genetic manipulation (overexpression/knockdown)

Understanding these tissue-specific considerations is crucial for selecting appropriate antibodies and developing optimized protocols for specific research applications.

What are the future prospects for AKR1C3 antibodies in personalized medicine applications?

AKR1C3 antibodies hold significant potential in advancing personalized medicine:

• Companion diagnostic development:

  • AKR1C3 antibody-based assays may serve as companion diagnostics for emerging therapeutics

  • IHC protocols could be standardized and validated for clinical laboratory use

  • Quantitative scoring approaches like H-score provide objective patient stratification metrics

• Treatment response monitoring:

  • Serial biopsies analyzed with AKR1C3 antibodies may track therapeutic efficacy

  • Minimal residual disease detection in leukemia offers a model for other cancer types

  • Concordance between protein expression and functional activity can guide treatment decisions

• Resistance mechanism identification:

  • AKR1C3 antibodies can detect expression changes associated with treatment resistance

  • Co-expression with other biomarkers may identify resistance signatures

  • Post-translational modifications detected by specific antibodies could indicate altered function

• Implementation challenges:

  • Standardization across laboratories requires rigorous validation protocols

  • Clinical-grade antibodies with consistent lot-to-lot performance will be essential

  • Integration with other biomarkers necessitates multiplexed detection approaches